Britain and America have concluded a key bilateral deal that will maintain no duties on UK medicine exports being sold in the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on medicines through the NHS. This move secures that import taxes on these key exports will remain at zero for a timeframe of three years.
This agreement is in response to recent threats to significantly raise duties on branded pharmaceutical products, with potential rates floated as high as one hundred percent.
"This agreement between the United Kingdom reinforces the international landscape for cutting-edge drugs and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a statement noted.
Economic Significance
Pharmaceuticals are one of the Britain's biggest exports to the US, which is clearly the largest destination for major British pharmaceutical firms.
Trade data reveal that in the year to the end of last September, the UK sold drugs valued at over eleven billion pounds to the US. This value made up 17.4% of British export trade in that period.
"This guarantee safeguards employment, stimulates funding and paves the way for the UK to emerge as a worldwide center for medical research," a government official commented.
Specific UK Commitments
The pact includes several notable changes from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded 20%.
Industry Background
This agreement comes amid a ongoing dispute between the sector and the ministers over drug pricing and NHS adoption.
The disagreement were intensified by assertions that American consumers were charged a premium for the identical medicines than patients in the other developed nations.
Recently, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been announced toward US facilities.
A senior figure stated that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the last ten years.
